• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿昔洛韦和阿昔洛韦-氯倍他索纳米纤维乳膏与乳膏制剂治疗复发性唇疱疹的疗效比较。

Therapeutic effects of acyclovir and acyclovir-clobetasol nanofibers vs. cream formulation for recurrent herpes labialis.

机构信息

Pharmaceutical Research Center, Department of Pharmaceutics, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Dental Research Center, Department of Diagnosis of Oral and Dental Diseases, Faculty of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.

出版信息

BMC Oral Health. 2024 Nov 6;24(1):1348. doi: 10.1186/s12903-024-04948-6.

DOI:10.1186/s12903-024-04948-6
PMID:39506756
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11539845/
Abstract

OBJECTIVES

This study aims to compare the therapeutic effects of acyclovir nanofiber and acyclovir-clobetasol nanofiber formulations with their non-nano formulations (cream formulation) on recurrent labial herpes.

MATERIALS AND METHODS

Eighty patients with labial herpes lesions were divided into four groups, each receiving one of the following treatments: acyclovir-clobetasol nano patch, acyclovir-clobetasol cream, acyclovir nano patch, or acyclovir cream. Pain levels and recovery times were assessed. The Wilcoxon test compared pain levels, while the log-rank test compared healing and scabbing times.

RESULTS

Acyclovir-clobetasol nanofiber and cream, along with acyclovir nanofiber, significantly reduced symptoms compared to the acyclovir cream. The recovery and scabbing times were shorter in patients who received acyclovir-clobetasol formulations compared to those receiving acyclovir alone.

CONCLUSION

Acyclovir-clobetasol combinations accelerated recovery times compared to acyclovir alone. Additionally, nanofiber formulations demonstrated enhanced healing efficacy over cream formulations.

TRIAL REGISTRATION

This trial was retrospectively registered by Iranian Registry of Clinical Trials (IRCT) at 14/11/2023.

TRIAL REGISTRATION NUMBER

IRCT20230926059521N1.

摘要

目的

本研究旨在比较阿昔洛韦纳米纤维和阿昔洛韦-卤倍他索纳米纤维制剂与其非纳米制剂（乳膏制剂）在复发性唇疱疹治疗中的疗效。

材料和方法

将 80 例唇疱疹病变患者分为四组，分别接受以下治疗之一：阿昔洛韦-卤倍他索纳米贴剂、阿昔洛韦-卤倍他索乳膏、阿昔洛韦纳米贴剂或阿昔洛韦乳膏。评估疼痛水平和恢复时间。Wilcoxon 检验比较疼痛水平，对数秩检验比较愈合和结痂时间。

结果

与阿昔洛韦乳膏相比，阿昔洛韦-卤倍他索纳米纤维和乳膏以及阿昔洛韦纳米纤维均显著减轻了症状。与单独使用阿昔洛韦相比，接受阿昔洛韦-卤倍他索制剂的患者恢复和结痂时间更短。

结论

与单独使用阿昔洛韦相比，阿昔洛韦-卤倍他索联合用药加速了恢复时间。此外，纳米纤维制剂的愈合效果优于乳膏制剂。

试验注册

该试验由伊朗临床试验注册中心（IRCT）于 2023 年 11 月 14 日进行了回顾性注册。

注册号

IRCT20230926059521N1。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c31/11539845/7f08d86029f4/12903_2024_4948_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c31/11539845/9df09e7a89b5/12903_2024_4948_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c31/11539845/fb63fb291e97/12903_2024_4948_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c31/11539845/7f08d86029f4/12903_2024_4948_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c31/11539845/9df09e7a89b5/12903_2024_4948_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c31/11539845/fb63fb291e97/12903_2024_4948_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c31/11539845/7f08d86029f4/12903_2024_4948_Fig3_HTML.jpg

相似文献

1
Therapeutic effects of acyclovir and acyclovir-clobetasol nanofibers vs. cream formulation for recurrent herpes labialis.阿昔洛韦和阿昔洛韦-氯倍他索纳米纤维乳膏与乳膏制剂治疗复发性唇疱疹的疗效比较。
BMC Oral Health. 2024 Nov 6;24(1):1348. doi: 10.1186/s12903-024-04948-6.
2
A novel drug delivery system using acyclovir nanofiber patch for topical treatment of recurrent herpes labialis: A randomized clinical trial.一种使用阿昔洛韦纳米纤维贴剂的新型药物传递系统，用于局部治疗复发性唇疱疹的随机临床试验。
Clin Exp Dent Res. 2022 Feb;8(1):184-190. doi: 10.1002/cre2.512. Epub 2021 Dec 5.
3
Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial.伐昔洛韦和外用氯倍他索凝胶用于唇疱疹的发作期治疗：一项患者发起的双盲安慰剂对照试验。
J Eur Acad Dermatol Venereol. 2009 Mar;23(3):263-7. doi: 10.1111/j.1468-3083.2008.03047.x. Epub 2009 Jan 8.
4
Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group.喷昔洛韦乳膏治疗唇疱疹。一项随机、多中心、双盲、安慰剂对照试验。局部用喷昔洛韦协作研究组。
JAMA. 1997 May 7;277(17):1374-9.
5
The role of topical 5% acyclovir and 1% hydrocortisone cream (Xerese™) in the treatment of recurrent herpes simplex labialis.局部应用 5%阿昔洛韦和 1%氢化可的松乳膏（Xerese™）治疗复发性唇疱疹的作用。
Postgrad Med. 2010 Sep;122(5):1-6. doi: 10.3810/pgm.2010.09.2216.
6
Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials.阿昔洛韦乳膏治疗唇疱疹：两项随机、双盲、赋形剂对照、多中心临床试验结果
Antimicrob Agents Chemother. 2002 Jul;46(7):2238-43. doi: 10.1128/AAC.46.7.2238-2243.2002.
7
Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: results of a randomized, open-label trial.硅胶治疗复发性唇疱疹的效果与阿昔洛韦乳膏相当：一项随机、开放标签试验的结果。
J Dermatolog Treat. 2008;19(3):176-81. doi: 10.1080/09546630701593457.
8
Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Penciclovir Cream Herpes Labialis Study Group.喷昔洛韦乳膏治疗日光性唇疱疹：一项随机、双盲、安慰剂对照试验。喷昔洛韦乳膏唇疱疹研究组。
Clin Ther. 2000 Jan;22(1):76-90. doi: 10.1016/s0149-2918(00)87979-5.
9
Failure of acyclovir cream in treatment of recurrent herpes labialis.阿昔洛韦乳膏治疗复发性唇疱疹失败。
Br Med J (Clin Res Ed). 1985 Jul 6;291(6487):7-9. doi: 10.1136/bmj.291.6487.7.
10
Safety and tolerability of combination acyclovir 5% and hydrocortisone 1% cream in adolescents with recurrent herpes simplex labialis.5%阿昔洛韦与1%氢化可的松联合乳膏用于复发性唇疱疹青少年患者的安全性和耐受性
Pediatr Dermatol. 2012 Jan-Feb;29(1):105-10. doi: 10.1111/j.1525-1470.2011.01570.x. Epub 2011 Oct 17.

本文引用的文献

1
COMPARATIVE EFFICACY OF ANTIVIRAL AGENTS FOR PREVENTION AND MANAGEMENT OF HERPES LABIALIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.抗病毒药物预防和治疗唇疱疹的疗效比较：系统评价和网络荟萃分析。
J Evid Based Dent Pract. 2023 Mar;23(1):101778. doi: 10.1016/j.jebdp.2022.101778. Epub 2022 Sep 14.
2
Herpes Simplex Virus and Varicella Zoster Virus Infections in Cancer Patients.单纯疱疹病毒和水痘带状疱疹病毒感染在癌症患者中的情况。
Viruses. 2023 Feb 5;15(2):439. doi: 10.3390/v15020439.
3
An Insight into Current Treatment Strategies, Their Limitations, and Ongoing Developments in Vaccine Technologies against Herpes Simplex Infections.
深入了解针对单纯疱疹感染的当前治疗策略、其局限性以及疫苗技术的最新进展。
Vaccines (Basel). 2023 Jan 17;11(2):206. doi: 10.3390/vaccines11020206.
4
A Comprehensive Overview of Epidemiology, Pathogenesis and the Management of Herpes Labialis.唇疱疹的流行病学、发病机制及治疗的全面概述。
Viruses. 2023 Jan 13;15(1):225. doi: 10.3390/v15010225.
5
40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?阿昔洛韦注册 40 年后：我们是否需要新型抗疱疹药物？
Int J Mol Sci. 2022 Mar 22;23(7):3431. doi: 10.3390/ijms23073431.
6
Drug Delivery (Nano)Platforms for Oral and Dental Applications: Tissue Regeneration, Infection Control, and Cancer Management.用于口腔和牙科应用的药物输送（纳米）平台：组织再生、感染控制和癌症管理。
Adv Sci (Weinh). 2021 Feb 5;8(8):2004014. doi: 10.1002/advs.202004014. eCollection 2021 Apr.
7
Anti-herpes virus activity of the carnivorous botanical, Sarracenia purpurea.猪笼草属食肉植物抗疱疹病毒活性的研究
Sci Rep. 2020 Nov 3;10(1):18953. doi: 10.1038/s41598-020-76151-w.
8
Herpes simplex virus type I-infected disorders alter the balance between Treg and Th17 cells in recurrent herpes labialis patients.单纯疱疹病毒 I 型感染性疾病改变复发性唇疱疹患者中 Treg 和 Th17 细胞之间的平衡。
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420933099. doi: 10.1177/2058738420933099.
9
Herpesvirus latency.疱疹病毒潜伏。
J Clin Invest. 2020 Jul 1;130(7):3361-3369. doi: 10.1172/JCI136225.
10
Treatment of herpes labialis by photodynamic therapy: Study protocol clinical trial (SPIRIT compliant).光动力疗法治疗唇疱疹：研究方案临床试验（符合SPIRIT标准）
Medicine (Baltimore). 2020 Mar;99(12):e19500. doi: 10.1097/MD.0000000000019500.